Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression

Authors:

Abstract
No abstract available
Funding Information
  • HHS | National Institutes of Health (NIH) (R01CA172495)
  • U.S. Department of Defense (DOD) (W81XWH-15–1-0507)

This publication has 59 references indexed in Scilit: